SGLT2+DPP4 combinations are to be released next month

First release with a combination of 5 items,

The scheduled release of Envlo, a new domestic diabetes drug

Domestic DPP-4·SGLT-2 diabetes complex Zemidapa

As the three-drug regimen of diabetes treatment Metformin + SGLT2i + DPP4i is also covered from this month, the SGLT2i + DPP4i complex is expected to be released next month.

 

A total of five items are expected to hit the market in May.

 

However, according to the reimbursement standard, these drugs are reimbursed only when used in combination with Metformin.

 

According to the industry on the 13th, MSD Stegluzan, Boehringer Ingelheim Esglito, AstraZeneca Qtern, LG Chem Zemidapa, and Dong-A ST Sugadapa are expected to release benefits in May.

 

Since April, regardless of ingredients, the three-drug regimen of Metformin + SGLT2i + DPP4i has been applied, allowing these items to enter the market.

 

However, these combinations are difficult to use as monotherapy.

 

This is because the three-drug regimen, including metformin, in the clinical trial for approval proved the blood sugar-enhancing effect, and the SGLT2i + DPP4i two-drug regimen is not covered under the reimbursement standard.

 

The competitiveness of the combination drug, which contains two ingredients in one pill and enhances the convenience of taking it, has not been revealed due to the additional intake of metformin.

 

This is because benefits are applied even if a DPP-4 single drug is added to the commercially available Metformin + SGLT2 complex.

 

Metformin + SGLT2 combinations have been pouring out in droves due to the expiry of Dapagliflozin's patent on the 8th.

 

Perhaps conscious of this, some SGLT2i+DPP4i combinations, such as Qtern and Zemidapa, all of a sudden went on non-reimbursement sales this month.

 

Discussions on the two-drug regimen of SGLT2i + DPP4i are highly likely to resurface starting in September when Januvia's patent expires.

 

This is because many domestic pharmaceutical companies have received approval for the combination of Dapagliflozin + Sitagliptin and are aiming to release a benefit when the patent expires.

 

This is because the two-drug regimen of Dapagliflozin + Sitagliptin can still be used according to the approval.

 

However, the full co-payment is applied to one of the two drugs.

 

It is expected that there will be many reimbursement inquiries about the two-drug therapy in the field, conscious of confusion, and it is expected that the insurance authorities will somehow sort it out.

 

Meanwhile, the domestic SGLT-2i new drug Envlo, developed by Daewoong Pharmaceutical, recently concluded negotiations with the NHIS.

 

By accepting 90% of the price of this drug compared to alternative drugs, only the expected billing amount is negotiated without negotiation of the upper limit, and the reimbursement list is expected to be accelerated.